MicroRNA Market Study by Immunoassays, Next Generation Sequencing, miRNA Arrays, and PCR-Based Arrays for Research and Clinical Diagnostics from 2024 to 2034
Analysis of MicroRNA Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
MicroRNA Market Outlook (2024 to 2034)
The global microRNA market is estimated to reach US$ 619.3 million in 2024 and is forecast to reach a value of US$ 1,330.7 million by 2034, growing at a CAGR of 7.9% from 2024 to 2034.
The miRNA market is fueled by the continuous search for new therapeutic molecules that can be used as new drugs by biopharmaceutical companies. The demand for anti-miRNA compounds and specific miRNA inhibitors is increasing, as they can be used as therapeutic alternatives in clinical settings.
The market is being propelled by rising investments to produce profitable medications in RNA therapeutics. The microRNA industry has grown due to technological developments that have increased the sensitivity of miRNA detection. Some of the most recent approaches for miRNA identification include enzyme-free amplification, DSN-based strategies, and RCA-based approaches, stimulating market growth.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Catalysts Shaping the Landscape of the MicroRNA Industry
Technological developments in genomics, such as next-generation sequencing and microarray analysis, have greatly improved the capacity to detect and analyze microRNAs. The microRNA market expansion is facilitated by advancements that enable a more thorough and precise analysis of microRNA expression patterns.
The demand for microRNA in the healthcare sector is driven by the development of medicines and diagnostic technologies, as microRNAs have demonstrated encouraging potential as therapeutic targets and biomarkers for various disorders.
There is a rising need for educational initiatives and materials as the role of microRNAs in gene regulation and disease pathogenesis becomes more well-recognized. The increasing awareness of the potential of microRNA among scientists and medical practitioners is stimulating the adoption of microRNA research instruments and services.
|Estimated Market Value (2024E)
|US$ 619.3 million
|Forecasted Market Value (2034F)
|US$ 1,330.7 million
|Global Market Growth Rate (2024 to 2034)
|Next Generation Sequencing Segment Growth Rate (2024 to 2034)
|Biopharmaceutical Companies Segment Growth Rate (2024 to 2034)
|North America Market Share (2024)
|East Asia Market Share (2024)
|Key Companies Profiled
Which Factors are Inhibiting the Growth of the MicroRNA Market?
“Stability, Clearance, and Cost Constraints”
MicroRNA-based therapy development, research, and clinical testing are quite expensive, which hinders market growth. High development costs and uncertain commercial outcomes discourage academic and industry participants in the miRNA market.
Targeting specific microRNAs for therapeutic purposes is difficult since many diseases involve different deregulating genes and pathways. The intricacy of illnesses restricts the efficacy of microRNA-based therapies, hampering sales of microRNA.
One of the major obstacles is getting microRNA-based medicines into the target cells efficiently. Overcoming obstacles, including in vivo cellular uptake, stability, and clearance, presents significant problems that impede the conversion of microRNA research into clinically useful applications.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
The microRNA market in North America is expected to accelerate at a CAGR of 7.3% through 2034. The increasing product demand in developed nations, particularly the United States and Canada, primarily contributes to the upsurge. The United States holds an estimated 82.5% of the industry.
The market in East Asia is expected to flourish at a 9.3% CAGR through 2034. Japan holds a share of 39.4% of the East Asian market.
What is the Key Trend Shaping the North American microRNA Market?
“Utilizing Therapeutic Potential of MicroRNA in Various Diseases”
The United States microRNA market is expanding due to increased partnerships between pharmaceutical corporations and academic institutions. The United States market is dynamic, as evidenced by the growing recognition of customized treatment and the significance of microRNA in illness diagnoses. In 2024, the United States is expected to capture 80.4% of the market share.
|United States Market CAGR
|United States Market Size (2024)
|US$ 196 million
|United States Market Size (2034)
|US$ 408 million
|Canada Market CAGR
|Canada Market Size (2024)
|US$ 33 million
|Canada Market Size (2034)
|US$ 57 million
The Canada microRNA market is expanding due to an increasing focus on biomarker identification and diagnostics, which has implications for the development of customized healthcare. A favorable regulatory framework and government efforts that promote investment in life sciences contribute to the market’s growth. In 2024, Canada is expected to hold 13.6% of the market share.
What is Driving the Asia Pacific MicroRNA Market?
“Advances in RNA-based Therapies Contribute to the Evolution of the Market”
Japan's aging population is spurring the adoption of microRNA, emphasizing age-related illnesses and healthcare issues. Japan's strong biotechnology industry and dedication to innovation are helping the country establish itself as an important microRNA supplier in the developing field of microRNA research and applications in the Asia Pacific. In 2024, Japan is expected to command a 40.6% market share of microRNA.
|Japan Market CAGR
|Japan Market Size (2024)
|US$ 32 million
|Japan Market Size (2034)
|US$ 77 million
|China Market CAGR
|China Market Size (2024)
|US$ 25 million
|China Market Size (2034)
|US$ 63 million
The country's rising chronic illness prevalence compels the demand for microRNA research and applications in China's healthcare system. China's biotechnology market is expanding due to government programs and investments geared toward customized health advances. China's ascent to prominence in the Asia Pacific market is largely due to the growth of creative startups and a robust biopharmaceutical industry. In 2024, China is poised to account for 30.9% of the market share.
Based on the assay type, the PCR-based arrays segment is estimated to hold a 38.8% market share by 2034. Simultaneously, the next-generation sequencing segment is anticipated to secure a noteworthy 28.7% share by 2034, contributing significantly to the market's resource diversity and stability.
Based on end users, the academic and research institutes segment marks its dominance, with a share of 37.3% by 2034. Followed by the biopharmaceutical companies’ segment in the end user category, garnering a share of 36.7% by 2034.
What Escalates PCR Arrays Segment to Lead in MicroRNA Market?
“Cost-Effectiveness of PCR Technology”
|PCR Based Assays
|Market Size (2024)
|US$ 226.1 million
|Market Share (2024)
Since PCR-based arrays are scalable, many microRNAs can be profiled simultaneously, yielding deep insights and securing a leading spot in the market. The market leadership of PCR-based assays is fueled by their quick turnaround time, which is in line with the demand for microRNA analysis that is both efficient and swift.
The broad accessibility and ease of use of PCR-based array technologies and their well-established methods promote the widespread adoption of microRNA. In 2024, the PCR-based arrays segment share is predicted to reach 36.5%.
What Role Do Academic and Research Institutes Play in Fueling Market Growth?
“Academic Dedication and Collaborative Efforts Propelling MicroRNA Advancements”
|Academic And Research Institutes
|Market Size (2024)
|US$ 236.6 million
|Market Share (2024)
Due to their emphasis on expanding scientific understanding and comprehending biological processes, the academic and research institutes segment is expected to be the catalysts behind microRNA research. These institutions are essential in microRNA research because they promote cooperation and deepen our understanding of biological processes.
Academic institutions function as training bases for emerging scientists, guaranteeing continued interest and expansion in microRNA study. The academic and research institutes segment is predicted to account for 38.2% of the market share in 2024.
Academic insights are helpful to biopharmaceutical companies, but because of their focus on basic research, they are the core influencers. In 2024, the biopharmaceutical companies segment is projected to account for 32.4% of the market share.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Key players in the microRNA industry include Merck KGaA, QIAGEN, Thermo Fisher Scientific Inc., Synlogic, GeneCopoeia, Inc., Horizon Discovery Ltd., New England Biolabs, Quantabio, NanoString, BioGenex, SeqMatic LLC, Miltenyi Biotec, Agilent Technologies, Inc., Promega Corporation, Abcam plc, and Kaneka Corporation.
The global microRNA market is characterized by dynamic trends and fierce competition. Leading microRNA vendors consistently allocate resources to research and development to expand their range of products. Strategic alliances, partnerships, and acquisitions to fortify market positions characterize the competitive landscape. Innovations in the microRNA industry are driven by the demand for microRNA-based diagnostics and treatments, creating a competitive climate.
Manufacturers of microRNA concentrate on growing their geographic reach and serving a range of applications across different healthcare sectors. Regulatory compliance and permissions are very important in determining how the competitive dynamics are shaped. The miRNA market is growing quickly, and businesses are competing for a significant portion to keep up with the rising medical needs and technological improvements.
Notable Innovations and Breakthroughs
- In October 2023, Thermo Fisher Scientific announced plans to invest US$ 3.1 billion to purchase Olink Holding AB to broaden its life sciences portfolio, which supports drug discovery.
- In November 2023, QIAGEN released new QIAcuity digital PCR kits and enhanced software to support customers in the biopharma and food safety industries in increasing their use.
- In November 2022, researchers from the American College of Surgeons, Chicago, reported an article that microRNA can be used as a biomarker to enhance the long-term prognoses for breast cancer patients.
- Singapore-based biotechnology company MiRXES disclosed additional capabilities in August 2022, including two new laboratories, an Industry 4.0 production facility, and a collaborative multi-cancer screening research program. The most recent developments support the goal of MiRXES, which is to increase research and production capabilities to develop miRNA-based diagnostics.
- In February 2022, researchers from the University of Illinois Urbana developed a brand-new microRNA point-of-care test for cancer screening. The test uses nanoparticles to collect tumor-specific microRNAs from human serum.
Segmentation of MicroRNA Market Research
By Assay Type :
- Next Generation Sequencing
- miRNA Arrays
- PCR Based Arrays
By Application :
- Clinical Diagnostics
By End User :
- Academic & Research Institutes
- Biopharmaceutical Companies
- Diagnostic Centers
- Clinical Research Organizations
By Region :
- North America
- East Asia
- East Asia
- South Asia and Pacific
- Western Europe
- Eastern Europe
- Middle East and Africa
- FAQs -
What was the MicroRNA Market Size in 2019?
The global miRNA market was worth US$ 419.7 million in 2019.
What is the Sales Outlook for MicroRNAs in 2024?
The sales of microRNAs are likely to be valued at US$ 619.3 million in 2024.
What is the Demand Forecast for MicroRNAs?
The demand for microRNAs is projected to reach a market value of US$ 1,330.7 million by 2034.
What is the Growth Projection for the MicroRNA Market?
The adoption of microRNA is projected to rise at a CAGR of 7.9% from 2024 to 2034.
At What CAGR is the Market in North America Predicted to Grow?
The North America market is forecasted to expand at a CAGR of 7.3% from 2024 to 2034.
At What CAGR is the Market in East Asia Predicted to Grow?
The East Asia market is projected to expand at a CAGR of 9.3% through 2034.